Vision RT reins in £250,000 for US push:
This article was originally published in Clinica
Executive Summary
London, UK-based 3D imaging specialist Vision RT has secured £250,000 ($504,000) in financing from new investor The Capital Fund in a bid to support its operations in the US. "We have recently appointed a director of sales, North America, who is establishing a direct sales and marketing presence for us in the US," company founder and CEO Dr Norman Smith told Clinica. The investment, which is part of a larger financing round, will also be used to further develop the company's patent-pending technology, the GateCT and GateRT 3D tracking platforms.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.